



## Bristol Myers Squibb (USA): Merger with Celgene Corporation

### Changes in FTSE RAFI™ Index Series

18 November 2019

Subject to the completion of the cash and stock merger between Bristol Myers Squibb (USA, constituent) and Celgene Corporation (USA, constituent), please see details of affected indexes and effective dates below:

Index	Effective From Start of Trading
FTSE RAFI All World 3000 Index	21 November 2019
FTSE RAFI All World 3000 Index - QSR	21 November 2019
FTSE RAFI Developed 1000 Index	21 November 2019
FTSE RAFI Developed 1000 Index - QSR	21 November 2019
FTSE RAFI US 1000 Index	21 November 2019
FTSE RAFI US 1000 Index - QSR	21 November 2019
FTSE RAFI Kaigai 1000 Index	21 November 2019

\*Based upon the stock merger terms of one share of Bristol Myers Squibb for every share of Celgene Corporation held.

For further information please contact FTSE Russell Client Services at [info@ftserussell.com](mailto:info@ftserussell.com) or call:

Australia	+1800 653 680
Hong Kong	+852 2164 3333
Japan	+81 3 4563 6346
London	+44 (0) 20 7866 1810
New York	+1866 551 0617

Alternatively please visit our website at [www.ftserussell.com](http://www.ftserussell.com)

[Terms of Use](#) | Copyright © 2019 FTSE Russell